Menu Search
Equities

Medexus Pharmaceuticals Inc

MDP:TOR

Medexus Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)2.55
  • Today's Change0.05 / 2.00%
  • Shares traded21.00k
  • 1 Year change-15.28%
  • Beta1.9522
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Medexus Pharmaceuticals Inc had net income fall from a gain of 1.22m to a loss of 214.00k despite a 4.59% increase in revenues from 108.10m to 113.05m. An increase in the cost of goods sold as a percentage of sales from 44.46% to 47.36% was a component in the falling net income despite rising revenues.
Gross margin52.50%
Net profit margin1.00%
Operating margin9.13%
Return on assets0.70%
Return on equity3.95%
Return on investment1.33%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Medexus Pharmaceuticals Inc fell by 7.81m. However, the company earned 18.71m from its operations for a Cash Flow Margin of 16.55%. In addition the company used 3.48m on investing activities and also paid 23.05m in financing cash flows.
Cash flow per share0.3979
Price/Cash flow per share6.55
Book value per share1.81
Tangible book value per share-2.24
More ▼

Balance sheet in USDView more

Medexus Pharmaceuticals Inc has a Debt to Total Capital ratio of 58.97%, a lower figure than the previous year's 111.94%.
Current ratio1.10
Quick ratio0.4928
Total debt/total equity1.44
Total debt/total capital0.5897
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.